Galectin Therapeutics Inc. (GALT)

NASDAQ: GALT · IEX Real-Time Price · USD

2.420

-0.090 (-3.59%)

At close: Jul 19, 2024, 4:00 PM

2.450

+0.030 (1.24%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Galectin Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2000
Selling, General & Admin	5.99	5.94	6.62	6.36	5.47	5.97	Upgrade
Research & Development	31.39	32.13	31.74	23.82	17.98	7.47	Upgrade
Operating Expenses	37.38	38.07	38.35	30.18	23.44	13.44	Upgrade
Operating Income	-37.38	-38.07	-38.35	-30.18	-23.44	-13.44	Upgrade
Interest Expense / Income	3.38	2.79	1.03	0.49	0.09	0.09	Upgrade
Other Expense / Income	3.89	3.82	-0.61	-0.14	-0.07	-0.23	Upgrade
Pretax Income	-44.65	-44.69	-38.78	-30.53	-23.47	-13.29	Upgrade
Net Income	-44.65	-44.69	-38.78	-30.53	-23.47	-13.29	Upgrade
Preferred Dividends	0.13	0.12	0.1	0.17	0.14	6.89	Upgrade
Net Income Common	-44.78	-44.81	-38.87	-30.7	-23.6	-20.18	Upgrade
Shares Outstanding (Basic)	62	60	59	59	57	52	Upgrade
Shares Outstanding (Diluted)	62	60	59	59	57	52	Upgrade
Shares Change	4.20%	1.29%	1.48%	2.63%	9.17%	32.54%	Upgrade
EPS (Basic)	-0.74	-0.74	-0.65	-0.52	-0.41	-0.39	Upgrade
EPS (Diluted)	-0.74	-0.74	-0.65	-0.52	-0.41	-0.39	Upgrade
Free Cash Flow	-34.28	-32.97	-31.06	-24.31	-20.6	-10.85	Upgrade
Free Cash Flow Per Share	-0.55	-0.55	-0.52	-0.41	-0.36	-0.21	Upgrade
EBITDA	-41.25	-41.86	-37.71	-30	-23.34	-13.17	Upgrade
Depreciation & Amortization	0.01	0.03	0.03	0.04	0.04	0.04	Upgrade
EBIT	-41.26	-41.89	-37.74	-30.04	-23.38	-13.21	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).